|
Report Date : |
28.03.2013 |
IDENTIFICATION DETAILS
|
Name : |
Pfizer Pharmaceutical India PRIVATE LIMITED |
|
|
|
|
Formerly Known
as: |
Warner-lambert india private limited |
|
|
|
|
Registered
Office : |
Pfizer Centre 5 Patel Estate, Off S V Road, Jogeshwari (West), Mumbai
– 400102, Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
02.01.1995 |
|
|
|
|
Com. Reg. No.: |
084206 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.2510.131 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24117MH1995FTC084206 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMW02375C |
|
|
|
|
PAN No.: [Permanent Account No.] |
AADCP5293L |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer, Importer and Exporter of Drugs and Pharmaceutical
Products. |
|
|
|
|
No. of Employees
: |
200 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
B (33) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Maximum Credit Limit : |
USD 20076448 |
|
|
|
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having a moderate track record. The latest
financials are not made available with the government department. As per previous year’s, there appears some accumulated losses recorded
by the company. However, Networth of the company seems to be strong. Trade relations
are reported to be fair. Business is active. Payments are reported to be
unknown. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
INDIAN ECONOMIC OVERVIEW
India is developing into an open-market economy, yet traces
of its past autarkic policies remain. Economic liberalization, including
industrial deregulation, privatization of state-owned enterprises, and reduced
controls on foreign trade and investment, began in the early 1990s and has
served to accelerate the country's growth, which has averaged more than 7% per
year since 1997. India's diverse economy encompasses traditional village
farming, modern agriculture, handicrafts, a wide range of modern industries,
and a multitude of services. Slightly more than half of the work force is in
agriculture, but services are the major source of economic growth, accounting
for more than half of India's output, with only one-third of its labor force.
India has capitalized on its large educated English-speaking population to
become a major exporter of information technology services and software
workers. In 2010, the Indian economy rebounded robustly from the global
financial crisis - in large part because of strong domestic demand - and growth
exceeded 8% year-on-year in real terms. However, India's economic growth in
2011 slowed because of persistently high inflation and interest rates and
little progress on economic reforms. High international crude prices have
exacerbated the government's fuel subsidy expenditures contributing to a higher
fiscal deficit, and a worsening current account deficit. Little economic reform
took place in 2011 largely due to corruption scandals that have slowed legislative
work. India's medium-term growth outlook is positive due to a young population
and corresponding low dependency ratio, healthy savings and investment rates,
and increasing integration into the global economy. India has many long-term
challenges that it has not yet fully addressed, including widespread poverty,
inadequate physical and social infrastructure, limited non-agricultural
employment opportunities, scarce access to quality basic and higher education,
and accommodating rural-to-urban migration.
|
Source
: CIA |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION PARTED BY (GENERAL DETAILS)
|
Name : |
Mr. V C Iyer |
|
Designation : |
Admin Department |
|
Contact No.: |
91-22-66932000 |
|
Date : |
26.03.2013 |
LOCATIONS
|
Registered Office : |
Pfizer Centre 5 Patel Estate, Off S V Road, Jogeshwari (West), Mumbai
– 400102, Maharashtra, India |
|
Tel. No.: |
91-22-66932000 |
|
Fax No.: |
91-22-66932444 |
|
Email: |
|
|
Website : |
|
|
Location : |
Owned |
|
|
|
|
Factory 1 : |
Thane Belapur Road, K U Bazar Post, Turbhe, Navi Mumbai – 400075,
Maharashtra, India |
|
Tel. No.: |
91-22-67916161 |
|
Fax No.: |
91-22-67916161 |
|
|
|
|
Regional Centers : |
Vasundhara, 9th
Floor, 2/7 - Sarat Bose Road, Kolkata - 700 020. Pfizer Centre, DLF
Building 9B, 4th Floor, Tower B, DLF Cybercity, Phase III, Gurgaon - 122
002, Haryana.
|
DIRECTORS
AS ON 31.08.2012
|
Name : |
Mr. Venkatesh Srinivasan |
|
Designation : |
Director |
|
Address : |
1104, Building No.5, Raheja Classique, Andheri West, Mumbai – 400053,
Maharashtra, India |
|
Date of Birth/Age : |
08.05.1967 |
|
Date of Appointment : |
04.01.2007 |
|
DIN No.: |
01251380 |
|
|
|
|
Name : |
Ms. Dipali G P Talwar |
|
Designation : |
Whole Time Director |
|
Address : |
10-C, Balmoral Hall, Mount Mery Road, Bandra West, Mumbai – 400050,
Maharashtra, India |
|
Date of Birth/Age : |
26.05.1969 |
|
Date of Appointment : |
10.04.2006 |
|
DIN No.: |
00189957 |
|
|
|
|
Name : |
Mr. Balu A V Sirnivasan |
|
Designation : |
Director |
|
Address : |
3rd Floor, Ritechoice Sri Skanda Nivas Apartment, 24 (Old 15),
Subramania Nagar – 1, Street, Kodambakkam, Chennai – 600024, Tamilnadu,
India |
|
Date of Birth/Age : |
06.02.1959 |
|
Date of Appointment : |
20.03.2006 |
|
Date of Ceasing: |
05.03.2012 |
|
DIN No.: |
00397658 |
|
|
|
|
Name : |
Mr. Joydeep Krishna Kant |
|
Designation : |
Director |
|
Address : |
Flat No.7/8, Shimra, 16th Road, Near Khar Gymkhana, Khar
West, Mumbai – 400052, Maharashtra, India |
|
Date of Birth/Age : |
10.01.1957 |
|
Date of Appointment : |
01.09.2007 |
|
DIN No.: |
01818820 |
|
|
|
|
Name : |
Mr. Anil Ram Bhavanani |
|
Designation : |
Director |
|
Address : |
B-23, Mayfair Garden, New Delhi – 110016, Delhi, India |
|
Date of Birth/Age : |
07.09.1963 |
|
Date of Appointment : |
01.10.2010 |
|
DIN No.: |
03299605 |
|
|
|
|
Name : |
Mr. Mohanish Lalit Anand |
|
Designation : |
Director |
|
Address : |
101, West View Apartment, Jaywant Sawant Road, Dahisar West, Mumbai –
400068, Maharashtra, India |
|
Date of Birth/Age : |
30.01.1973 |
|
Date of Appointment : |
01.10.2010 |
|
Date of Ceasing: |
15.11.2011 |
|
DIN No.: |
02957496 |
KEY EXECUTIVES
|
Name : |
Mr. V C Iyer |
|
Designation : |
Admin Department |
|
|
|
|
Name : |
Mr. Farah Tehmton Irani |
|
Designation : |
Secretary |
|
Address : |
403, Meher Homes, Station Road, Jogeshwari West, Mumbai – 400102,
Maharashtra, India |
|
Date of Birth/Age : |
15.04.1982 |
|
Date of Appointment : |
01.02.2008 |
|
PAN No.: |
AAVPI5166Q |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 31.08.2012
|
Names of Shareholders |
|
No. of Shares |
|
Warner – Lambert Co. LLC, USA |
|
125506523 |
|
Parke Davis and Co. LLC, USA |
|
20 |
|
Pfizer Luxembourg SARL, Luxembourg |
|
125506543 |
|
Total |
|
251013086 |
AS ON 31.08.2012
|
Category |
Percentage |
|
Foreign holdings( Foreign institutional
investor(s), Foreign companie(s) Foreign financial institution(s),
Non-resident Indian(s) or Overseas Corporate bodies or Others |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer, Importer and Exporter of Drugs and Pharmaceutical
Products. |
|
|
|
|
Imports : |
|
|
Products : |
Raw Materials |
|
Countries : |
China |
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit, Cheque |
|
|
|
|
Purchasing : |
Cash and Credit |
GENERAL INFORMATION
|
Customers : |
Industries |
|||||||||
|
|
|
|||||||||
|
No. of Employees : |
200 (Approximately) |
|||||||||
|
|
|
|||||||||
|
Bankers : |
Not Divulged |
|||||||||
|
|
|
|||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
B S R and Company Chartered Accountant |
|
Address : |
Lodha Excelus 1st Floor, Apollo Mills Compound N.M Joshi Marg Mahalakshmi Mumbai- 400011, India |
|
|
|
|
Ultimate Holding
Company: |
Pfizer Inc., USA |
|
|
|
|
Joint venture
investors : |
Warner-Lambert Company LLC, USA Holding 50% of the voting rights with effect from 27 January 2010 (holds 125,506,543 Equity Shares of Rs 10/- each as at 31 March 2011) Pfizer Luxembourg SARL Holding 50% of the voting rights with effect from 27 January 2010 (holds 125,506,543 Equity Shares of Rs 10/- each as at 31
March 2011) |
|
|
|
|
Subsidiaries : |
Capsugel Healthcare Limited, India Pfizer Animal Health India Limited (formerly known as
Vetnex Animal Health Limited) |
|
|
|
|
Fellow subsidiaries
*: (with whom transactions have taken place during the year): |
* Subsidiaries of the joint
venture investors w.e.f. 27th January 2010 |
CAPITAL STRUCTURE
AS ON 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
270000000 |
Equity Shares |
Rs.10/- |
Rs.2700.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
251013086 |
Equity Shares |
Rs.10/- |
Rs.2510.131 Millions |
|
|
|
|
|
Footnotes
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.09.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
2510.131 |
2510.131 |
1752.873 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
2826.740 |
2822.616 |
0.000 |
|
|
4] (Accumulated Losses) |
(317.759) |
(269.693) |
(158.480) |
|
|
NETWORTH |
5019.112 |
5063.054 |
1594.393 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
0.000 |
0.000 |
0.000 |
|
|
2] Unsecured Loans |
2865.000 |
2450.000 |
1897.335 |
|
|
TOTAL BORROWING |
2865.000 |
2450.000 |
1897.335 |
|
|
DEFERRED TAX LIABILITIES |
27.048 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
7911.160 |
7513.054 |
3491.728 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1651.535 |
1803.445 |
1463.944 |
|
|
Capital work-in-progress |
9.572 |
41.633 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
4176.912 |
4216.665 |
1548.365 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
0.347
|
4.348 |
0.416 |
|
|
Sundry Debtors |
239.158
|
331.328 |
302.560 |
|
|
Cash & Bank Balances |
307.238
|
321.427 |
10.151 |
|
|
Other Current Assets |
169.123
|
178.263 |
168.844 |
|
|
Loans & Advances |
1710.797
|
1012.799 |
239.735 |
|
Total
Current Assets |
2426.663
|
1848.165 |
721.706 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
79.731
|
64.466 |
157.981 |
|
|
Other Current Liabilities |
218.835
|
297.326 |
57.830 |
|
|
Provisions |
54.956
|
35.062 |
26.476 |
|
Total
Current Liabilities |
353.522
|
396.854 |
242.287 |
|
|
Net Current Assets |
2073.141
|
1451.311 |
479.419 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
7911.160 |
7513.054 |
3491.728 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.09.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
TOTAL |
1299.021 |
1136.808 |
955.530 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
TOTAL |
NA |
NA |
NA |
|
|
|
|
|
|
|
|
|
(LOSS) / PROFIT FOR
THE YEAR BEFORE EXCEPTIONAL ITEMS AND TAX |
(13.019) |
(111.212) |
71.178 |
|
|
|
|
|
|
|
|
|
|
EXCEPTIONAL
ITEMS |
0.000 |
0.000 |
3.462 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
(13.019) |
(111.212) |
71.178 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
35.048 |
0.000 |
12.500 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
(48.067) |
(111.212) |
58.678 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
(269.692) |
(158.480) |
(217.158) |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
(317.759) |
(269.692) |
(158.480) |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
NA |
40.046 |
77.335 |
|
|
TOTAL EARNINGS |
NA |
40.046 |
77.335 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
NA |
2.136 |
0.928 |
|
|
|
Stores & Spares |
NA |
29.365 |
3.831 |
|
|
|
Capital Goods |
NA |
11.794 |
149.301 |
|
|
TOTAL IMPORTS |
NA |
43.295 |
154.06 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share |
(0.19) |
(0.59) |
-- |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.09.2009 |
|
PAT / Total Income |
(%) |
(3.70)
|
(9.78) |
6.14 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
NA
|
NA |
NA |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
(0.32)
|
(30.42) |
3.26 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
--
|
(0.02) |
0.04 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt/Networth) |
|
0.57
|
0.48 |
1.19 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
6.86
|
4.66 |
2.98 |
LOCAL AGENCY FURTHER INFORMATION
SUNDRY CREDITORS DETAILS:
PARTICULARS
|
Rs.
In Millions 31.03.2011 |
Rs.
In Millions 31.03.2010 |
Rs.
In Millions 31.03.2009 |
Sundry Creditors due others
|
79.731 |
64.466 |
157.981 |
|
|
|
|
|
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
Yes |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
Yes |
|
9] |
Name of person contacted |
Yes |
|
10] |
Designation of contact
person |
Yes |
|
11] |
Turnover of firm for last
three years |
Yes |
|
12] |
Profitability for last
three years |
Yes |
|
13] |
Reasons for variation
<> 20% |
-------- |
|
14] |
Estimation for coming
financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister
concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
Yes |
|
20] |
Export / Import details
(if applicable) |
Yes |
|
21] |
Market information |
---------------------- |
|
22] |
Litigations that the firm
/ promoter involved in |
---------------------- |
|
23] |
Banking Details |
No |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking
account |
---------------------- |
|
26] |
Buyer visit details |
No |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if
applicable |
Yes |
|
29] |
Last accounts filed at
ROC |
No |
|
30] |
Major Shareholders, if
available |
Yes |
|
31] |
Date of Birth of
Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director,
if available |
No |
|
33] |
Voter ID No of
Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating,
if available |
No |
BUSINESS OVERVIEW:
During the year, the Company recorded a Net Revenue of Rs.1299.021
Millions, an increase of 14% percent over Rs.1136.808 Millions in the previous
year. The Company incurred a Net Loss After Tax of Rs.48.067 Millions as
compared to a Net Loss After Tax of Rs.111.212 Millions for the previous year.
The accumulated loss for the year has increased from Rs.1584.80 Lakhs to
Rs.269.692 Millions.
The Company’s activities during the year comprise of trading exports,
trading in empty vegetable capsules, Veterinary Medicine Pharmaceutical
Sciences (VMPS) and Pfizer Accelerated Solution Centre, India (PASCI). The VMPS
division is carrying out activities of Research and Development in Veterinary
Medicines on lab scale and Pilot Plant scale for Pfizer Inc., USA and its affiliates.
The PASCI division provides information technology development, application
management and integration, in a multi-vendor co-located model, for IT projects
assigned by Pfizer Inc., or, its affiliates.
In addition to the above, the Company also renders various support
services to Pfizer Inc., USA and its affiliates.
SUBSIDIARY
COMPANIES:
CAPSUGEL
HEALTHCARE LIMITED:
The Net Sales of Capsugel Healthcare Limited for the year ended March
31, 2011 is Rs.314.308 Millions as compared to Rs.223.034 Millions for the
previous year. The operations for the period reflect a Net Loss of Rs.188.206
Millions as against a Net Loss of Rs.138.721 Millions for the previous year.
The Company’s shareholding in Capsugel Healthcare Limited increased to
99.75% ( 19,32,11,569 Equity Shares) on July 21, 2011 pursuant to conversion of
unsecured loans (including outstanding interest) amounting to Rs.92,30,00,000
into Equity Share Capital by allotment of 9,23,00,000 Equity Shares at face
value of Rs.10 each.
Pfizer Inc, USA, the Ultimate Holding Co. had announced the global
divesture of Capsugel Division. Accordingly, the Company entered into a Stock
Transfer Agreement dated August 1, 2011 for transfer of its entire shareholding
in Capsugel Healthcare Limited to Capsugel Belgium BVBA for a consideration of
Rs.2693.454 Millions. The Company also entered into an Asset Transfer Agreement
dated August 1, 2011 with Capsugel Healthcare Limited for the sale and transfer
of assets listed therein at a consideration of Rs.21.020 Millions.
Capsugel Healthcare Limited ceased to be a Subsidiary of the Company
with effect from August 2, 2011.
PFIZER ANIMAL
HEALTH INDIA LIMITED:
The Net Sales of Pfizer Animal Health India Limited for the year ended
March 31, 2011 is Rs.1050.451 Millions as compared to Rs.1001.699 Millions for
the previous year. The operations for the period reflect a Net Loss of
Rs.113.121 Millions as against a Net loss of Rs.238.331 Millions for the
previous year.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.27 |
|
|
1 |
Rs.82.49 |
|
Euro |
1 |
Rs.69.88 |
INFORMATION DETAILS
|
Information
Gathered by : |
PLK |
|
|
|
|
Report Prepared
by : |
SDA |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
4 |
|
PAID-UP CAPITAL |
1~10 |
4 |
|
OPERATING SCALE |
1~10 |
3 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
3 |
|
--PROFITABILIRY |
1~10 |
4 |
|
--LIQUIDITY |
1~10 |
4 |
|
--LEVERAGE |
1~10 |
4 |
|
--RESERVES |
1~10 |
4 |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
33 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.